Related Experiment Video

Updated: Jul 15, 2026

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Treatment of pediatric multiple sclerosis and variants

D Pohl1, E Waubant, B Banwell

  • 1Department of Pediatrics and Pediatric Neurology, Georg-August-University Goettingen, Germany.

Neurology
|April 18, 2007
PubMed

Insights

Early treatment with disease-modifying therapies (DMT) benefits pediatric multiple sclerosis (MS) patients. While DMTs approved for adults are increasingly used in children, long-term safety and efficacy data are still needed.

Area of Science:

  • Pediatric Neurology
  • Neuroimmunology
  • Clinical Therapeutics

Background:

  • Multiple sclerosis (MS) significantly impacts adult patients, with early treatment improving prognosis.
  • Currently, no disease-modifying therapies (DMTs) are specifically approved for pediatric MS.
  • Existing guidelines for adult MS therapies do not extend to pediatric populations.

Purpose of the Study:

  • To review current knowledge and experiences with DMTs in pediatric MS.
  • To summarize safety and tolerability data of DMTs in children and adolescents with MS.
  • To provide an overview of symptomatic MS therapies in pediatric patients.

Main Methods:

  • Review of recent small cohort studies on DMT safety and tolerability in pediatric MS.
  • Analysis of reported side effects for interferon beta (IFNB) and glatiramer acetate (GA) in pediatric patients.
  • Synthesis of data on MS variants treated in pediatric centers.

Main Results:

  • Reported side effects of IFNB and GA in pediatric MS appear comparable to adult data.
  • Long-term tolerability, safety, and efficacy of DMTs in pediatric MS remain largely unestablished.
  • Increasing use of adult-approved DMTs in children and adolescents with MS is noted.

Conclusions:

  • Early initiation of DMTs is crucial for improving long-term outcomes in pediatric MS.
  • Further research is essential to establish long-term safety and efficacy of DMTs in pediatric MS.
  • Symptomatic treatments for pediatric MS also require further investigation.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...